Quantcast

Latest Anti-diabetic drug Stories

2010-07-14 08:00:00

YINCHUAN, China, July 14 /PRNewswire-Asia/ -- Recently, Xinhua Website reported about Dr. Nie Wentao's nutrition intervention technology for type 1 diabetes mellitus. Dr. Nie Wentao's diabetic treatment technology is becoming a mainstream technology for diabetes treatment, so it aroused widespread concern in China. Dr. Nie Wentao, having engaged in the study of nutrition interventions on diabetes mellitus for a long period, has great influence in the field of diabetes treatment in China....

2010-06-29 06:00:00

ORLANDO, Fla. and CARLSBAD, Calif., June 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that data from seven programs in Isis' broad metabolic disease franchise were presented at the American Diabetes Association's (ADA) 70th Scientific Sessions in Orlando. These presentations included two oral talks highlighting data from Isis' Phase 2 study of ISIS 113715 in patients with type 2 diabetes and Isis' Phase 1 study of ISIS-GCGRRx. Isis and...

2010-06-28 07:00:00

TOKYO, June 28 /PRNewswire/ -- Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, "Astellas") announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine. The oral presentation, along with...

2010-06-17 12:33:00

SAN DIEGO, June 17 /PRNewswire/ -- Profil(TM) Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the appointment of Prof. Dr. Lutz Heinemann as Director of Scientific Services and Robert J. Schott, MD, MPH, FACC as Director of Cardiometabolic Research. Prof. Dr. Heinemann will oversee the scientific aspects of Profil's integrated approach from clinical trial protocol design to the publication of study...

2010-06-15 08:32:00

KALAMAZOO, Mich., June 15 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) will present its research providing insights into the mechanisms and novel activities of its drug portfolio at the American Diabetes Association's (ADA) 70th annual Scientific Sessions conference in Orlando, Fla., which is being held on June 25-29, 2010. The ADA conference is widely considered to be the world's leading scientific and medical meeting focused on diabetes. MSDC Chief Scientific Officer...

2010-06-08 11:00:30

New study suggests that medication used to control blood sugar levels can distort results of some molecular imaging screenings for cancer A study presented at SNM's 57th Annual Meeting suggests that medication ingested to control blood-sugar levels can skew the results of cancer screenings using positron emission tomography (PET), a molecular imaging technique, by increasing absorption in the gut of the PET imaging agent called fluorodeoxyglucose (18F-FDG), which mimics sugar inside the...

2010-06-07 20:10:59

Researchers from the La Jolla Institute and University of Virginia find protein key to insulin secretion If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy &...

2010-05-06 07:00:00

PRINCETON, N.J., May 6 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) announced today details of the company's cardiovascular outcomes trial for Victoza® (liraglutide [rDNA origin] injection), which is set to start in the autumn of 2010. The trial named LEADER(TM) (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) aims to assess and confirm the cardiovascular safety of the company's new once-daily human GLP-1 analog...

2010-03-15 15:27:31

COLUMBUS, Ohio "“ An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research. The drug consists of a synthetic molecule that stops the biological activity of a protein called macrophage migration inhibitory factor, or MIF. This protein is implicated in a number of diseases because it is...

2010-03-14 07:00:00

EAST HANOVER, N.J., March 14 /PRNewswire/ -- Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition. Primary data from the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial, initiated in 2001, were presented today at the...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related